摘要
目的:系统评价西格列汀联合其他降糖药物治疗2型糖尿病的疗效和安全性。方法:计算机检索Cochrane图书馆、PubMed、EMbase、中国期刊全文数据库,查找西格列汀联合其他降糖药物治疗2型糖尿病的随机对照试验(RCT),按照Cochrane系统评价方法对纳入研究进行质量评价后,采用RevMan5.1统计学软件对提取的数据进行Meta分析。结果:共纳入17项RCT,合计3643例患者。Meta分析结果显示,西格列汀组在降低患者糖化血红蛋白(HbA1c)水平[WMD=-0.23,95%CI(-0.40,-0.06),P<0.05]、空腹血糖(FPG)水平[WMD=-0.70,95%C(I-1.21,-0.18),P<0.05]、体质量指数[WMD=-1.67,95%C(I-2.02,-1.32),P<0.05]方面,均优于对照组,两组比较差异有统计学意义;西格列汀组患者低血糖发生例数亦显著低于对照组,两组比较差异有统计学意义[RR=0.36,95%C(I0.16,0.82),P<0.05]。结论:西格列汀联合其他降糖药物能有效控制2型糖尿病患者血糖水平,且安全性较好,但其远期疗效及安全性有待开展更多高质量、大样本、长期随访的RCT加以验证。
OBJECTIVE：To evaluate therapeutic efficacy and safety of sitagliptin combined with other glucose-lowering drugs in the treatment of type 2 diabetes.METHODS：Retrieved from Cochrane Library,PubMed,EMbase and CNKI,randomized controlled trials（RCT）about sitagliptin combined with other glucose-lowering drugs in the treatment of type 2 diabetes were collected.The quality of included literatures was evaluated according to the Cochrane Collaboration system review,and then Meta-analysis was performed using Rev Man 5.1 software.RESULTS：A total of 17 RCT were included,involving 3 643 patients.Results of meta-analysis showed that HbA 1 c [WMD=-0.23,95%CI（-0.40,-0.06）,P0.05],FPG [WMD=-0.70,95%C（I-1.21,-0.18）,P0.05] and body weight index [WMD=-1.67,95%CI（-2.02,-1.32）,P0.05] of sitagliptin group were better than those of control group,there was statistical significance.The number of hypoglycemia events in sitagliptin group was significantly lower than in control group,there was statistical significance [RR=0.36,95%CI（0.16,0.82）,P0.05].CONCLUSIONS：Sitagliptin can effectively control the blood glucose in patients with type 2 diabetes with sound safety.But its long-term efficacy and safety still need to be confirmed by performing more high quality,large-scale RCT with long-term following-up.
出处
《中国药房》
CAS
CSCD
2013年第32期3028-3033,共6页
China Pharmacy
